Mackinnon S, Barnett L, Bourhis J H, Black P, Heller G, O'Reilly R J
Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021.
Blood. 1992 Dec 15;80(12):3235-41.
Determining both myeloid and lymphoid chimerism after T-cell-depleted allogeneic bone marrow transplantation (BMT) could be helpful in the understanding of the biology of engraftment and could provide a rational method of assessing the ability of different conditioning regimens to promote engraftment. We prospectively investigated the role of different pretransplant conditioning regimens in 29 leukemic patients post-BMT by assessing myeloid and T-cell chimerism using a rapid and sensitive polymerase chain reaction (PCR) method. Minisatellites are hypervariable regions of DNA consisting of tandem repeats of a core nucleotide sequence, and allelic polymorphism results from differences in the number of the repeats. We used this variation to distinguish between donor and recipient cells post-BMT. Seventeen patients (9 sibling and 8 unrelated donors) received conditioning with hyperfractionated total body irradiation (TBI), thiotepa, and cyclophosphamide (Cy). Of the other 12 patients (all sibling donors), 11 received TBI plus Cy plus another agent: VP16, carboplatinum, or AZQ. One patient received TBI plus thiotepa plus VP16. All but one of the patients studied received marrow from HLA-identical donors. PCR analysis confirmed donor lymphoid engraftment within 8 days of transplant in six of six patients studied. All granulocyte DNA was of donor origin within the first 4 weeks of transplant, regardless of the conditioning regimen. The day +28 T cells were exclusively of donor origin in 14 of 17 patients who received TBI plus thiotepa plus Cy, but were mixed chimeric in 10 of 12 patients who received other conditioning regimens (P < .001). Early graft rejection was seen in one unrelated transplant recipient conditioned with TBI plus thiotepa plus Cy. Late graft failure was observed in 3 of 12 patients with mixed T-cell chimerism and in none of 16 patients with full donor chimerism at day +28. However, 5 of 16 patients who had complete T-cell chimerism at day +28 developed acute graft-versus-host disease (GVHD), whereas no patient with mixed chimerism had acute GVHD. Our results indicate that minisatellite PCR is a rapid and sensitive method for assessing chimerism post-BMT, that the donor T cells are important for consistent durable engraftment, and that TBI plus thiotepa plus Cy may be superior to the other regimens studied in inducing full donor chimerism. Larger numbers and longer follow-up are necessary to confirm these data and also to assess the relationship between complete donor T-cell chimerism and leukemia-free survival.
确定T细胞去除的异基因骨髓移植(BMT)后的髓系和淋巴系嵌合状态,有助于理解植入生物学,并可为评估不同预处理方案促进植入的能力提供合理方法。我们采用快速灵敏的聚合酶链反应(PCR)方法评估髓系和T细胞嵌合状态,前瞻性研究了29例白血病患者BMT后不同移植前预处理方案的作用。微卫星是由核心核苷酸序列串联重复组成的DNA高变区,等位基因多态性源于重复序列数量的差异。我们利用这种变异来区分BMT后的供体和受体细胞。17例患者(9例同胞供体和8例无关供体)接受了超分割全身照射(TBI)、噻替哌和环磷酰胺(Cy)预处理。另外12例患者(均为同胞供体)中,11例接受了TBI加Cy加另一种药物:依托泊苷、卡铂或AZQ。1例患者接受了TBI加噻替哌加依托泊苷。除1例患者外,所有研究患者均接受了HLA配型相合供体的骨髓。PCR分析证实,在研究的6例患者中,有6例在移植后8天内出现供体淋巴细胞植入。无论预处理方案如何,移植后前4周所有粒细胞DNA均来自供体。接受TBI加噻替哌加Cy的17例患者中,有14例在第28天T细胞完全来自供体,但接受其他预处理方案的12例患者中有10例为混合嵌合(P<0.001)。1例接受TBI加噻替哌加Cy预处理的无关移植受者出现早期移植排斥。在第28天,12例混合T细胞嵌合患者中有3例出现晚期移植失败,16例完全供体嵌合患者中无一例出现晚期移植失败。然而,在第28天完全T细胞嵌合的16例患者中有5例发生了急性移植物抗宿主病(GVHD),而混合嵌合患者中无一例发生急性GVHD。我们的结果表明,微卫星PCR是评估BMT后嵌合状态的快速灵敏方法,供体T细胞对持续稳定植入很重要,TBI加噻替哌加Cy在诱导完全供体嵌合方面可能优于其他研究方案。需要更大样本量和更长随访时间来证实这些数据,并评估完全供体T细胞嵌合与无白血病生存之间的关系。